"Product Pipeline includes Evoltra (Clofarabine), Modrenal (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom"   
Approximate Financial Snapshot as of 5/24/07
Shares Outstanding 55.1M
52 Wk Hi/Lo 6.41/


Market Cap $271.9M
Recent Price $4.94



Bioenvision (BIVN)


New Horizon. New Science.


Bioenvision is currently developing products for hematologic malignancies, solid tumors and autoimmune diseases.

Bioenvision is planning to develop products for other therapeutic areas as well. In addition, the Company has in-licensed technologies to reduce the impact of blood-borne and hospital-acquired infections.

Bioenvision's product line can be viewed here

BIVN Investor Highlights

  • Bioenvision has teamed up with Genzyme Corp. to develop clofarabine, a treatment for leukemia in children, the magazine said. Bioenvision aims to expand its use for elderly patients with acute myeloid leukemia in Europe, where it has marketing rights.
  • Steven Rouhandeh, chief executive of SCO, is quoted by BusinessWeek as saying that when Europe approves clofarabine for adults, "Bioenvision will rocket," adding that by then, Genzyme might opt to buy Bioenvision. A decision is expected in 2007.
  • Soros Fund Management and Perseus-Soros BioPharma Fund own a combined 12 percent stake in BIVN according to BusinessWeek. 


Bioenvision (BIVN) primary focus is the acquisition, development and marketing of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: Evoltra, Modrenal (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy), and other products. Bioenvision is also developing Suvus which is currently in clinical development for refractory chronic hepatitis C infection.

The company also offers various anti-infective technologies, including the OLIGON technology, an advanced biomaterial that has been incorporated into various FDA approved medical devices. In addition, it provides an animal health product, Vetoryl, for the treatment of Cushing's disease in dogs; and Velostan, a cytostatic drug under investigation as an anticancer agent and as an antimicrobial. The company sells its products to wholesale distributors and directly to hospitals, clinics, and retail pharmacies in the United States and the United Kingdom. It has co-development partnership with Genzyme Corporation. 

Recent News and Press Releases

Big investors flock to tiny Bioenvision -magazine

Bioenvision Reports Third Quarter 2007 Financial Results

Bioenvision Receives $7.4 Million in Warrant Exercises by Perseus-Soros Biopharmaceutical Fund & SCO Capital

For the latest News and Quotes on BIVN Click Here.

Three Month Chart


Bioenvision Inc.

345 Park Avenue
41st Floor
New York, NY 10154
Phone: 212-750-6700
Fax: 212-750-6777

SEC Filings

BIVN filings with the SEC can be found here. All Fillings are current and the Company is fully reporting.



Disclaimer feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. For continuing coverage of BIVN, please sign up for our free newsletter. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

Copyright All rights reserved. is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act  of 1933, Section 17(b), will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the web site. has not been compensated by Bioenvision nor do we hold any shares at this time. may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “expects’”, “will,” “anticipates,” “estimates, “believes,” or that by statements indicating certain actions “may,” “could,” or “might” occur.


We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: and/or the National Association of Securities Dealers (NASD) at: . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.